https://www.entradatx.com/ | Texto ancla | Skip to Main Content |
https://www.entradatx.com/ | | Sin texto |
https://ir.entradatx.com/ | Externo Subdominio | Investor Relations |
https://www.entradatx.com/contact | Subdominio | Contact |
/accessibility | Subdominio | Accessibility |
https://www.linkedin.com/compa... | Externo Subdominio | LinkedIn |
https://www.entradatx.com/about | Subdominio | Who We Are |
https://www.entradatx.com/about | Subdominio | About On a mission to treat devastating diseases with intracellular therapeutics |
https://www.entradatx.com/about | Subdominio Texto ancla | Leadership Decades of experience in the development of therapeutics and expertise in rare diseases |
https://www.entradatx.com/about | Subdominio Texto ancla | Social Responsibility Our values fuel our innovation |
/platform | Subdominio | Platform |
/platform | Subdominio | Intracellular Therapeutics Working to address the fundamental challenges of conventional intracellular therapeutics |
/platform | Subdominio Texto ancla | EEV™ Platform Designed to engage disease-causing targets previously considered inaccessible and undruggable |
/platform | Subdominio Texto ancla | Broad Therapeutic Potential Modular approach supports efficient expansion into multiple therapeutic areas |
/pipeline | Subdominio | Pipeline |
/pipeline | Subdominio | Pipeline We are creating a diverse and expanding portfolio of oligonucleotide, antibody and enzyme-based programs |
https://www.entradatx.com/dmd | Subdominio | Duchenne Muscular Dystrophy Program Our programs represent a differentiated approach to developing potential treatments for patients with Duchenne |
https://www.entradatx.com/dm1 | Subdominio | Myotonic Dystrophy Type 1 Program Our second program offers a potentially innovative approach to reach the intracellular disease-causing target for patients ... |
/manuscripts | Subdominio | Publications |
/manuscripts | | View All |
/manuscripts/ | | Endosomal Escape Vehicle Platform Enhances the Delivery of Oligonucleotides in Preclinical Models of Neuromuscular Disorders |
/manuscripts/ | | Cell-Penetrating Peptides Escape the Endosome by Inducing Vesicle Budding and Collapse |
/manuscripts/ | | Understanding Cell Penetration of Cyclic Peptides |
/manuscripts/ | | Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides |
/presentations | Texto duplicado | View All |
/presentations/ | | The Endosomal Escape Vehicle Platform Enhances Lipid Nanoparticle-Mediated Delivery of Genomic Medicines |
/presentations/ | | Utility of a 3D–Engineered Skeletal Muscle Organoid System to Assess Exon Skipping, Dystrophin Protein Restoration, and Functional Improvement in a Human DMD... |
/patients | Subdominio | Patients |
/patients | Subdominio | Patients At Entrada, our efforts are guided by you – the people and families we are working to help |
https://www.entradatx.com/dreams | Subdominio | DREAMS Grant Program Learn more about our competitive grant program to advance diversity, equity, inclusion and accessibility |
https://www.entradatx.com/careers | Subdominio | Careers |
https://www.entradatx.com/careers | Subdominio Texto ancla | Our Values See the values that bind us together |
https://www.entradatx.com/careers | Subdominio Texto ancla | Employee Benefits View our comprehensive and generous financial and wellness benefits |
https://www.entradatx.com/careers | Subdominio Texto ancla | Open Positions Learning more about working at Entrada |
https://www.entradatx.com/about | Subdominio | About |
https://www.entradatx.com/about | | Leadership |
https://www.entradatx.com/about | | Social Responsibility |
/platform | Subdominio | Intracellular Therapeutics |
/platform | | EEV™ |
/platform | | Therapeutic Potential |
/pipeline | Subdominio Texto duplicado | Pipeline |
https://www.entradatx.com/dmd | Subdominio | Duchenne Muscular Dystrophy |
https://www.entradatx.com/dm1 | Subdominio | Myotonic Dystrophy Type 1 Program |
/manuscripts | Subdominio | Manuscripts |
/presentations | Subdominio | Presentations |
/patients | Subdominio Texto duplicado | Patients |
https://www.entradatx.com/dreams | Subdominio | DREAMS Grant Program |
https://www.entradatx.com/careers | | Our Values |
https://www.entradatx.com/careers | | Employee Benefits |
/careers/ | | Open Positions |
https://ir.entradatx.com/ | Externo Subdominio | IR Home |
https://ir.entradatx.com/news-... | Externo Subdominio | News Releases |
https://ir.entradatx.com/events | Externo Subdominio | Events |
https://ir.entradatx.com/prese... | Externo Subdominio Texto duplicado | Presentations |
https://ir.entradatx.com/stock... | Externo Subdominio | Stock Information |
https://ir.entradatx.com/corpo... | Externo Subdominio | Corporate Governance |
https://ir.entradatx.com/finan... | Externo Subdominio | Financial Information |
https://ir.entradatx.com/inves... | Externo Subdominio | FAQs |
https://ir.entradatx.com/email... | Externo Subdominio | Email Alerts |
https://ir.entradatx.com/conta... | Externo Subdominio | Contact IR |
https://www.linkedin.com/compa... | Externo Subdominio Texto duplicado | LinkedIn |
/accessibility | Subdominio Texto duplicado | Accessibility |
/privacy-policy | Subdominio | Privacy Policy |
/terms-of-use | Subdominio | Terms of Use |
https://www.entradatx.com/contact | Subdominio Texto duplicado | Contact |
https://www.entradatx.com/about | Subdominio Texto duplicado | About |
/pipeline | Subdominio Texto duplicado | Pipeline |
https://ir.entradatx.com/news-... | Externo Subdominio Texto duplicado | View All |
http://ir.entradatx.com/news-r... | Externo Subdominio | Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program |
http://ir.entradatx.com/news-r... | Externo Subdominio | Texto ancla no relevante Read More |
http://ir.entradatx.com/news-r... | Externo Subdominio | Entrada Therapeutics Reports Second Quarter 2024 Financial Results |
http://ir.entradatx.com/news-r... | Externo Subdominio Texto duplicado | Texto ancla no relevante Read More |
http://ir.entradatx.com/news-r... | Externo Subdominio | Entrada Therapeutics Announces $100 Million Registered Direct Offering |
http://ir.entradatx.com/news-r... | Externo Subdominio Texto duplicado | Texto ancla no relevante Read More |
https://www.entradatx.com/about | Subdominio | Learn More |
/platform | Subdominio Texto duplicado | Learn More |
/pipeline | Subdominio Texto duplicado | Learn More |
https://www.entradatx.com/careers | Subdominio Texto duplicado | Learn More |
https://www.entradatx.com/careers | Texto duplicado | Open Positions |
https://www.entradatx.com/careers | | 2023 Best Places to Work Presented by Biospace - see our open positions |
https://www.entradatx.com/careers | | Boston Globe Best Places to Work in Massachusetts 2023 - see our open positions |
https://www.entradatx.com/careers | | Winner MassEcon Impact Award - see our open positions |
https://www.entradatx.com/about | Subdominio | Who We Are Meet our leadership team |
/platform | Subdominio | Platform Learn about our EEV™ Platform |
/pipeline | Subdominio | Pipeline Discover our pipeline of programs |
https://www.entradatx.com/careers | Subdominio | Careers Apply to our open positions |
https://ir.entradatx.com/news-... | Externo Subdominio | Newsroom Read the latest press releases |
https://www.entradatx.com/contact | Subdominio | Get in Touch Contact Entrada Therapeutics |
https://www.entradatx.com/ | | Sin texto |
/privacy-policy | Texto duplicado | Privacy Policy |
/terms-of-use | Texto duplicado | Terms of Use |
/privacy-policy | Texto duplicado | Privacy Policy |
/terms-of-use | Texto duplicado | Terms of Use |
https://www.entradatx.com/ | Nueva ventana | OK |
(Deseable)